Posts by Clinical Trial Centers

Upcoming Conferences: AAIC & NDD

July 22-26, Alliance representatives are attending the Alzheimer’s Association International Conference® (AAIC) in Chicago.   July 30-August 1, we’ll be in Boston for the Neuropsychiatric Drug Development Summit (NDD).   We look forward to hearing from knowledgeable speakers and meeting with industry associates to discuss our capabilities and extensive experience with Alzheimer’s and other mental…

Read More

Dr. Kathleen Anne Welsh-Bohmer, PhD joins NeuroCog Trials as VP for Neurodegenerative Disorders

  Specializing in Alzheimer’s Disease (AD) and other neurological and age-related disorders, Dr. Kathleen Anne Welsh-Bohmer, Professor of Psychiatry and Neurology at Duke University, joins the accomplished scientific team at NeuroCog Trials (NCT) providing thought leadership in Neurodegenerative Disorders. With more than 25 years of research dedicated to this therapeutic area, Dr. Welsh-Bohmer lends the…

Read More

David Walling, PhD Quoted in Press Release Announcing FDA Approval of Alkermes’ ARISTADA INITIO™ for Schizophrenia

Alkermes plc today announced that the U.S. Food and Drug Administration (FDA) has approved ARISTADA INITIO™ (aripiprazole lauroxil) for the initiation of ARISTADA® (aripiprazole lauroxil), a long-acting injectable atypical antipsychotic for the treatment of schizophrenia in adults. For the first time, ARISTADA INITIO, in combination with a single 30 mg dose of oral aripiprazole, provides…

Read More

Collaborative Neuroscience Network Receives Certificate of Achievement from IQVIA

Site Recognition Award commemorates exceptional performance of Collaborative Neuroscience Network.

Read More

David Walling, PhD Discusses Misconceptions and New Developments Around Schizophrenia in Interview with MD Magazine

At the American Psychiatric Associations’ annual meeting in New York City, David Walling, PhD, CEO and Principal Investigator for Collaborative Neuroscience Network, sat down with MD Magazine to talk about the biggest misconceptions about patients with schizophrenia—including the high rate of suicide among this patient population—and what’s being done to address them. He also spoke…

Read More

Upcoming Conferences: SIRS, APA, and ASCP

April 4-8, Alliance representatives are attending the Schizophrenia International Research Society (SIRS) Conference in Florence, Italy.   May 5-9, we’ll be in New York City for the American Psychiatric Association (APA) Annual Meeting.   May 28-June 1, we’re attending the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida.   We look forward…

Read More

Link to Dr. Gary Kay’s Webinar: “Evaluating Your Compound’s Impact on Driving”

Check out the recording of Dr. Gary Kay’s recent webinar, “Evaluating Your Compound’s Impact on Driving.” (Skip to the three-minute mark for the beginning of the webinar.) In this informative webinar, Cognitive Research Corporation‘s President, Gary Kay, Ph.D., assists you in understanding and implementing FDA requirements for evaluating your compound’s impact on driving. An expert…

Read More

Don’t Let Translations Slow Down Your Trial

  Don’t Let Translations Slow Down Your Trial Accelerate It With Accurate, On-Time Translations Get Your Quote in 24hrs or Less! Rely on a company that understands your study’s cultural and scientific nuances without sacrificing the deadline. No matter your timeline, timezone, or language, NCT Linguistics can provide your team with 100% accurate and on-time…

Read More

2018 Conference Date eCards from the Alliance

As we ring in the new year, we’ve identified some prominent industry conferences in 2018, and added the dates and locations to our annual e-card for your reference. With our Alliance’s growth, we now have a CNS-focused card and a medical version. Both are included below. Alliance principals and partners are presenting at and attending…

Read More
Page 1 of 812 »